how can i get rid or the human papilloma virus?

by Rachel on May 24, 2010

I GOT Because vaginal intraepithelial neoplasia HPV

{ 4 comments… read them below or add one }

gooplic May 24, 2010 at 5:41 am

i dont think it is something you can get rid of

TLH May 24, 2010 at 6:24 am

this will most likely clear on it’s own your immune system will take care of it.you also can get the hpv vaccine.

callykatrina13 May 24, 2010 at 6:27 am

According to recent guidelines drafted by the CDC, “examination of sex partners is not necessary” as follow-up to an abnormal Pap smear. It’s certainly possible–even likely–that the partner is or has been infected with the virus, although highly unlikely that he will ever show any symptoms. Nor is it possible to determine whether he can spread HPV to a future partner.

Unfortunately, medical opinion is not settled on this point. The closest to a consensus might be phrased as, “Don’t be too sure.” Transmission of HPV poses a major challenge to researchers, not only because it involves sexual behavior, which people may or may not feel free to talk about, but also because HPV’s long and variable period of latency makes it virtually impossible to trace back to a specific partner.

When considering the infectiousness of treated or untreated warts, therefore, researchers must fall back on indirect observations and on reasoning from what they do know about this virus. Some specialists think that removing genital warts may lower the risk of transmission, since it “de-bulks” the areas of tissue that contain infectious particles. But since the area surrounding any visible warts is also likely to contain infectious HPV particles, removing the warts cannot eliminate the risk.

A person may have good reasons for wanting his or her genital warts removed–they may be uncomfortable physically or psychologically. But removing warts cannot guarantee that the risk of transmission is removed.

Warts and dysplasia do recur in some cases, but by no means all. When they recur, they show varying persistence: Some people experience just one more episode, and others several. The good news for most people is that with time, the immune system seems to gain some mastery over the virus, making recurrences less frequent and often eliminating them entirely within about two years.

As for ordinary genital warts, says Doug Lowy, MD, chief of the Laboratory of Cellular Oncology at the National Cancer Institute, “These are caused by HPV types that are virtually never found in cancer.” These are the “low-risk” types, 6, 11, 42, 43, and 44. When not causing genital warts they may cause a transient abnormality in Pap smear results, or most often produce no symptoms at all.

There are more than 70 types of human papillomavirus, and most are quite specific in the sites they can invade and the pathology they can cause. Those most strongly associated with cancer are HPV types 16, 18, 31, 45, and, to a lesser degree, half a dozen others. These are known as the “high-risk” types, not because they usually or frequently cause cancer–in fact, cervical cancer is a rare disease in the United States today, and penile cancer even more so–but because, in the infrequent event that cancer does develop, it can usually be traced back to one of these types. Even so, it bears repeating: most women with high-risk HPV on their cervix will not develop cervical cancer.

The truth, however, is that the fleshy growths we call genital warts are almost always benign. In the vast majority of cases, they do not lead to cancer, turn into cancer, or predispose a person toward developing cancer.

According to Katherine Stone, MD, a member of ASHA’s HPV Scientific Advisory Committee, genital warts need not “raise a red flag with regard to cancer in anyone’s mind

In practical terms, a man with genital warts is no more likely than any other sexually active man to transmit cancer-causing HPV types to a partner. Experts do recommend that a woman exposed to genital warts–or any other STD–have regular Pap smears. This is because she may have been exposed to high-risk HPV types during unprotected sexual activity. Regular Pap tests are also recommended for any sexually active woman, since HPV infection is very common. It is worth keeping in mind that both men and women may be infected with, and infectious for, high-risk HPV, regardless of whether or not they have genital warts.

Provisional HPV Vaccine Recommendations
The HPV vaccine is recommended for 11-12 year-old girls, but can be administered to girls as young as 9 years of age. The vaccine also is recommended for 13-26 year-old females who have not yet received or completed the vaccine series.
Ideally, the vaccine should be administered before onset of sexual activity. However, females who are sexually active also may benefit from vaccination. Females who have not been infected with any vaccine HPV type would receive the full benefit of vaccination. Females who already have been infected with one or more HPV type would still get protection from the vaccine types they have not acquired. Few young women are infected with all four HPV types in the vaccine. Currently, there is no test available for clinical use to determine whether a female has had any or all of the four HPV types in the vaccine.
HPV Vaccine Safety
The HPV vaccine has been tested in over 11,000 females (9-26 years of age) in many countries around the world, including the United States (U.S).
These studies found that the HPV vaccine was safe and caused no serious side effects. Adverse events were mainly injection site pain. This reaction was common but mild.
A detailed and coordinated post-licensure safety monitoring plan is in place.
There is no thimerosal or mercury contained in the vaccine.
HPV Vaccine Efficacy
The efficacy of this vaccine has mainly been studied in young women (16-26 years of age) who previously had not been exposed to any of the four HPV types in the vaccine. These clinical trials have demonstrated 100% efficacy in preventing cervical precancers caused by the targeted HPV types, and nearly 100% efficacy in preventing vulvar and vaginal precancers and genital warts caused by the targeted HPV types.
The vaccine has no therapeutic effect on HPV-related disease. If a girl or woman is already infected with one of the HPV types in the vaccine, the vaccine will not prevent disease from that type.
The ACIP recommendation for vaccine use in girls as young as 9 years of age is based on ‘bridging’ immunogenicity and safety studies, which were conducted in about 1,100 females, 9-to-15 years of age. These studies demonstrated that over 99% of study participants developed antibodies after vaccination; titers were higher for young girls than for older females participating in the efficacy trials.
While it is possible that vaccination of males with the quadrivalent vaccine may offer direct health benefits to males and indirect health benefits to females, there are currently no efficacy data available to support use of HPV vaccine in males. Efficacy studies in males are ongoing. Information will be available in the future.
Duration of Vaccine Protection
The duration of vaccine protection is unclear. Current studies (with five-year followup) indicate that the vaccine is effective for at least five years. There is no evidence of waning immunity during that time period. This information will be updated as additional data regarding duration of immunity become available.
HPV Vaccine Delivery (Provisional Recommendations)
The vaccine should be delivered through a series of three intra-muscular injections over a six-month period. The second and third doses should be given 2 and 6 months after the first dose.
The vaccine can be administered at the same visit as other age-appropriate vaccines, such as Tdap, Td, MCV4, and hepatitis B vaccines.
The HPV vaccine can be given to females who have an equivocal or abnormal Pap test, a positive Hybrid Capture II® high risk test, or genital warts. However, women should be advised that data do not indicate that the vaccine will have any therapeutic effect on existing Pap test abnormalities, HPV infection or genital warts.
Lactating women can receive the HPV vaccine.
Immunocompromised females, either from disease or medication, can receive this vaccine; however, the immune response to vaccination and vaccine efficacy might be less than in immunocompetent females.
The HPV vaccine is not recommended for use in pregnancy. The vaccine has not been causally associated with adverse outcomes of pregnancy or adverse events to the developing fetus. However, data on vaccination in pregnancy are limited. Any exposure to vaccine in pregnancy should be reported to the vaccine pregnancy registry (800-986-8999).
The HPV vaccine is contraindicated for persons with a history of immediate hypersensitivity to yeast or to any vaccine component.
The HPV vaccine can be administered to people with minor acute illnesses (e.g., diarrhea or mild upper respiratory tract infections, with or without fever). Vaccination of people with moderate or severe acute illnesses should be deferred until after the illness improves.
Cervical cancer screening recommendations have not changed for females who receive the HPV vaccine.
Vaccine providers should notify vaccinated women that they should continue to receive regular cervical cancer screening for three reasons. First, the vaccine will NOT provide protection against all types of HPV that cause cervical cancer. Second, women may not receive the full benefits of the vaccine if they do not complete the vaccine series. Third, women may not receive the full benefits of the vaccine if they receive the vaccine after they have already acquired a vaccine HPV type.
Vaccine providers should notify vaccinated women that they should continue to practice protective sexual behaviors (e.g., abstinence, monogamy, limiting the number of sex partners, and using condoms, which may have a protective effect on HPV acquisition, reduce the risk for HPV-associated diseases, and mitigate the adverse consequences of infection with HPV1 ), since the vaccine will not prevent all cases of genital warts—nor will it prevent other sexually transmitted infections (STIs).
CDC has developed a list of vaccine questions and answers, which vaccine providers may find useful for patient discussions.
HPV Vaccine Cost
The private sector list price of the vaccine is $119.75 per dose (about $360 for full series).
The federal Vaccines for Children (VFC) Program will provide free vaccines to children and adolescents under 19 years of age, who are either uninsured, Medicaid-eligible, American Indian, or Alaska Native. There are over 45,000 sites that provide VFC vaccines, including hospital, private, and public clinics. The VFC Program also allows children and adolescents to receive VFC vaccines through Federally Qualified Health Centers or Rural Health Centers, if their private health insurance does not cover the vaccine.
Some states also provide free or low-cost vaccines at public health department clinics to people without health insurance coverage for vaccines.
While some insurance companies may cover the vaccine and cost of administration, others may not. Most large group insurance plans usually cover the costs of recommended vaccines. However, there is often a short lag-time after a vaccine is recommended, and before it is available and covered by health plans.
Cost Effectiveness of HPV Vaccine
Published cost-effectiveness studies of HPV vaccination suggest that the cost per quality-adjusted life year (or QALY) saved due to vaccination against HPV types 16 and 18 would be in the $15,000 to $25,000 range per QALY. These published estimates were calculated without including the benefits of preventing HPV types 6 and 11. If such benefits were included, the cost effectiveness of vaccination would appear more favorable.
Both the impact and cost-effectiveness of HPV vaccination were estimated assuming that vaccination occurs in addition to current cervical cancer screening programs in the U.S.
Policies for HPV Vaccination
There are no federal laws requiring immunization of children with HPV vaccine. School and childcare entry laws for all immunizations are state laws and vary from state to state.
Other Vaccines in Development
A bivalent HPV vaccine is in the final stages of clinical testing in females. This vaccine would protect against the two types of HPV (16,18) that cause 70% of cervical cancers.
Additional Information
Genital HPV Infection
Natural History of HPV
HPV-Associated Disease
Prevention of Cervical Cancer
See Also:
Human Papillomavirus Infection
http://www.cdc.gov/ncidod
http://www.cancer.org
http://www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html
Genital HPV Infection
HPV infection is the most common STI in the U.S., with approximately 20 million people currently infected. Each year, an additional 6.2 million people become newly infected in the U.S.2 As many as half of infected males and females with HPV are adolescents and young adults, 15-24 years of age.3
While most HPV infections are asymptomatic and transient, HPV is of clinical and public health importance because persistent infection with certain oncogenic types can lead to cervical cancer. Cervical cancer is one of the most common cancers in women worldwide. Certain oncogenic types also have been associated with other, less common anogenital cancers. Moreover, non-oncogenic HPV types can cause genital warts and, rarely, respiratory tract warts in children.
Over 40 types of HPV infect mucosal surfaces, including the anogenital epithelium (i.e., cervix, vagina, vulva, rectum, urethra, penis, and anus). Genital HPV can be divided into “high-risk” (i.e., oncogenic or cancer-associated) types, and “low-risk” (i.e., non-oncogenic) types.
HPV 16 and 18 are the most common high-risk types found in cervical cancer
HPV 6 and 11 are the most common low-risk types found in genital and respiratory tract warts
Natural history of HPV
Over half of sexually active women and men are infected with HPV at some point in their lives.4 Approximately 90% of women with HPV infection become HPV-negative within two years.5 The gradual development of an effective immune response is thought to be the likely mechanism for HPV DNA clearance. However, it is possible that the virus remains in a non-detectable dormant state and then reactivates many years later.

Many women with transient HPV infections may develop mild cytologic (Pap test) abnormalities that spontaneously regress.
About 10% of women infected with HPV develop persistent HPV infection. Women with persistent high-risk HPV infections are at greatest risk for developing high-grade cervical cancer precursor lesions (cervical intra-epithelial neoplasia or CIN 2,3) and cancer.
HPV-Associated Disease
Persistent infection with high-risk types of HPV is associated with almost all cervical cancers. The age-adjusted incidence rate for invasive cervical cancer in the U.S. was 8.7 per 100,000 women in 2002 (most recent year for which data are available).6 In that same year, 3,952 women died from cervical cancer in the U.S.
Persistent infection with high-risk types of HPV also is associated with cancers of the vulva, vagina, penis and anus. However, these cancers are considerably less common than cervical cancer.

Genital HPV infection with low-risk types of HPV is associated with genital warts in men and women. About 1% of sexually active adults in the U.S. have visible genital warts at any point in time.2

Rarely, perinatal transmission of low-risk HPV infections can result in respiratory tract warts in infants and children, a condition known as recurrent respiratory papillomatosis (RRP).

Prevention of Cervical Cancer
Cervical cancer once claimed the lives of more American women than any other type of cancer. But over the last 40 years, widespread cervical cancer screening using the Pap test and treatment of pre-cancerous cervical abnormalities have resulted in a marked reduction in cervical cancer incidence and mortality in the U.S.7 New technologies, such as liquid-based cytology and an HPV DNA test, are now commercially available and licensed for use in women for cervical cancer screening and management, although they are not recommended by all professional associations.

Today, as many as 82% of women in the U.S. have been screened with a Pap test in the past three years.8 Despite this, U.S. screening programs are not reaching all women in the U.S. It is estimated that half of the women diagnosed with cervical cancer have never been screened for cervical cancer, and an additional 10% have not been screened in the previous 5 years.5, 9 Cervical cancer disproportionately affects women of lower socioeconomic status, without regular access to health care, who are uninsured, and who are recent immigrants

[edit] Vaccine
Main article: HPV vaccine
On June 8, 2006, the FDA approved Gardasil, a prophylactic HPV vaccine which is marketed by Merck. The vaccine trial[1]
, conducted in adult women with a mean age of 23, showed protection against initial infection with HPV types 16 and 18, which together cause 70 percent of cervical cancers. HPV types 16 and 18 also cause anal cancer in men and women. The trial also showed 100% efficacy against persistent infections, not just incident infections. The vaccine also protects against HPV types 6 and 11, which cause 90 percent of genital warts. Women aged nine through twenty-six can be vaccinated, though the trial did not test minors. GlaxoSmithKline is expected to seek approval for a prophylactic vaccine targeting HPV types 16 and 18 early in 2007, known as Cervarix. Since the current vaccine will not protect women against all the HPV types that cause cervical cancer, it will be important for women to continue to seek Pap smear testing, even after receiving the vaccine. The Centers for Disease Control and Prevention (CDC) recommend vaccinating a woman who has already been diagnosed with HPV (October 2006)[1]. This vaccine represents the first time a medical approach to sexually transmitted disease does not address the risk of the other sexual partner, and also the first time a sexually transmitted disease prophylaxis is officially and specifically limited to heterosexuals

luv2lotto May 24, 2010 at 7:06 am

Your not alone, I have it too. I have also had cervical, vulvar, and anal dysplasia because of HPV. You can’t get rid of HPV, its up to your own body’s immune system to fight it off. You can try to help it along by eating right (lots of antioxidants), taking a mulit-vitamin, not smoking, and lowering your stress level, but there are no guarantees. The doctor can treat and remove the vaginal dysplasia, but he cannot remove the HPV, there is no cure for it.

Leave a Comment

Previous post:

Next post: